Cingulate shares plans to resubmit its ADHD candidate CTx-1301 to the FDA, following a CRL tied to CMC information requests
|Articles|March 24, 2020
PsychPearls: Battling Anxiety During the COVID-19 Pandemic
Author(s)Joshua C. Morganstein, MD
How can psychiatrists advise patients to manage their stress and to remain calm?
Advertisement
Dr Joshua Morganstein, Chair of the American Psychiatric Association Committee on the Psychiatric Dimensions of Disaster, answers this question: There is a lot of panic, and anxiety/stress is on the rise, even in people without mental illness. How can psychiatrists advise patients to manage this stress and to remain calm?
Have more COVID concerns and clinical tips? Email us at
Advertisement
Related to this article
The American Society of Addiction Medicine has released the first clinical guide and national resource for managing the intoxication and withdrawal of medetomidine.
Digital memory tests flag subtle preclinical Alzheimer changes, especially with neocortical tau; scalable tools may boost future trial screening.
How ED physicians and psychiatrists team up to cut mental health boarding, reduce unnecessary tests, and deliver faster, safer ED crisis care.
In the second positive phase 3 trial of lumateperone (Caplyta) for bipolar mania, participants saw improved manic symptoms vs placebo as early as day 3.
Lipocine has dosed the first participant in BLOOM, their phase 3 study evaluating LPCN 1154 (oral brexanolone) for postpartum depression.
Reach Out and Read serves 4.8 million children, but 23% of parents at 3 centers reported clinician modeling, tied to the greatest home literacy gains.
New data shows cannabis dominates teens’ substance-related ER visits, often with alcohol or stimulants, urging better screening and intervention for psychosis, vomiting.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Lumateperone Shows Significant and Rapid Improvement in Bipolar Mania
2
NDA Submission Complete: COMP360 Psilocybin for Treatment-Resistant Depression
3
New National Guidance for Managing Medetomidine Intoxication and Withdrawal
4
Updates on CTx-1301, NDA Resubmission After FDA Complete Response Letter
5